Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353356 | 0.89 | ITGB1 (0.49) | PPARAACEMEN1KMT2AL3MBTL1 | |
| SCHEMBL6357181 | 0.84 | ALDH1A1 (0.39) | PPARAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6355470 | 0.84 | MAPK1 (0.45) | MEN1KMT2A | |
| SCHEMBL6356512 | 0.82 | CNR1 (0.41) | PPARAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6355158 | 0.81 | PPARG (0.42) | PPARGPPARAACEPPARDMEN1 | |
| SCHEMBL6355586 | 0.80 | CNR1 (0.40) | PPARAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6355164 | 0.80 | ALDH1A1 (0.39) | PPARAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6355719 | 0.80 | ALDH1A1 (0.40) | PPARAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6356970 | 0.79 | P2RY14 (0.56) | ACEMEN1KMT2A | |
| SCHEMBL6485680 | 0.79 | PPARG (0.44) | PPARGPPARAACEPPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | ALLOS THERAPEUTICS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1206442-A4 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | UNIV VIRGINIA COMMONWEALTH (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
| EP-1206442-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014316-A1 | SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | PPARG 943/4885PPARA 1742/4885ACE 3873/4885 |
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | PPARG 943/4885PPARA 1742/4885ACE 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.